KT Corporation (030200.KS)
| Previous close | 37,000.00 |
| Open | 37,200.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 36,800.00 - 37,300.00 |
| 52-week range | 29,450.00 - 38,500.00 |
| Volume | |
| Avg. volume | 1,049,155 |
| Market cap | 8.718T |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 08 Aug 2022 - 12 Aug 2022 |
| Forward dividend & yield | 1,910.00 (5.30%) |
| Ex-dividend date | 29 Dec 2021 |
| 1y target est | 43,440.00 |
- Zacks
KT vs. PHI: Which Stock Should Value Investors Buy Now?
KT vs. PHI: Which Stock Is the Better Value Option?
- GlobeNewswire
UPDATE - KT Corporation and Hanmi Pharmaceutical promote business cooperation with Digital Pharm, a Korean company specializing in digital therapeutics and electroceuticals
KT and Hanmi Pharmaceutical to jointly invest in Digital Pharm, a company specializing in digital therapeutics and electroceuticalsLeading the domestic Korean digital therapeutics (DTx) market through mutual cooperation with Korea’s first ICT technology-medical institution-pharmaceutical companyAccelerated development of DTx related to alcohol and nicotine addiction and heart failure as well as domestic ADHD electroceuticals SEOUL, South Korea, June 20, 2022 (GLOBE NEWSWIRE) -- Digital platform
- GlobeNewswire
KT Corporation and Hanmi Pharmaceutical promote business cooperation with Digital Pharm, a Korean company specializing in digital treatment devices and electronic drugs
KT and Hanmi Pharmaceutical to jointly invest in Digital Pharm, a company specializing in digital treatment devices and electronic drugsLeading the domestic Korean digital therapeutics (DTx) market through mutual cooperation with Korea’s first ICT technology-medical institution-pharmaceutical companyAccelerated development of DTx related to alcohol and nicotine addiction and heart failure as well as domestic ADHD e-medication SEOUL, South Korea, June 20, 2022 (GLOBE NEWSWIRE) -- Digital platform
